Impact of the Therapeutic Education on the Quality of Life of the Child Suffering of Food Allergy IgE-mediated
NCT ID: NCT02106169
Last Updated: 2019-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2014-11-05
2016-10-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study also show us if therapeutic education has an effect on the quality of life of child's family.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Assessment of Quality of Life in Food Allergic Children
NCT01480427
The Feasibility of Systemic Reaction After Contact Exposure to the Allergenic Food in Children With Known Food Allergy
NCT05080127
Health Related Quality of Life in Children With Food Allergy: Comparison to Controls and Other Chronic Diseases
NCT02008643
Quality of Life and Eating Disorders in Children With FPIES, Food Allergy or Celiac Disease
NCT04643704
Master Allergen Child Nutrition. Reintroduction of Small Doses
NCT02384707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Food allergy limits the child socialisation, leads to anxiety/fear, and impairs health-related quality of life. In the day of today, there is no cure treatment. Also, improve the quality of life is one of the goals of the food allergy management.
The impact of therapeutic education on quality of life has never been studied. We intend to study the impact of therapeutic education on the quality of life of children from 8 to 12 years old with IgE mediated food allergy.
Our hypothesis is the quality of life can be improved by therapeutic education.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Therapeutic education group
At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the doctors offer patients randomized to therapeutic education to have a therapeutic education before the 4th month.
The sessions will be led by a multidisciplinary equip. Each child and his family will have a therapeutic session (2 times 2 hours).
Therapeutic education group
Control group
At first, all patients will be invited to participate in a study of troop having for objective to estimate their quality of life. Then, the patients randomized in this group will have the habitual medical care.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Therapeutic education group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Child from 8 to 12 years old (included)
* Family who can have an internet access
* Children which parents have received study's information
* Child who can have a medical examination before inclusion (art. L.1121-11 du CSP).
* Patients who have a medical insurance.
Exclusion Criteria
* Child with chronic disease, except asthma and atopic dermatitis
* Patients who already had a therapeutic education for food allergy
* Patient already included in another study
8 Years
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
French Society of Allergology
UNKNOWN
Stallergenes laboratories
UNKNOWN
Picot-Lactalis laboratory
UNKNOWN
ALK Industries
UNKNOWN
Assistance Publique - Hôpitaux de Paris
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chantal KARILA, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Necker hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Necker hospital
Paris, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A01104-41
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.